<?xml version="1.0" encoding="UTF-8"?>
<ref id="B273-pharmaceuticals-12-00147">
 <label>273.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Londino</surname>
    <given-names>J.D.</given-names>
   </name>
   <name>
    <surname>Lazrak</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Noah</surname>
    <given-names>J.W.</given-names>
   </name>
   <name>
    <surname>Aggarwal</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bali</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Woodworth</surname>
    <given-names>B.A.</given-names>
   </name>
   <name>
    <surname>Bebok</surname>
    <given-names>Z.</given-names>
   </name>
   <name>
    <surname>Matalon</surname>
    <given-names>S.</given-names>
   </name>
  </person-group>
  <article-title>Influenza virus M2 targets cystic fibrosis transmembrane conductance regulator for lysosomal degradation during viral infection</article-title>
  <source>FASEB J.</source>
  <year>2015</year>
  <volume>29</volume>
  <fpage>2712</fpage>
  <lpage>2725</lpage>
  <pub-id pub-id-type="doi">10.1096/fj.14-268755</pub-id>
  <pub-id pub-id-type="pmid">25795456</pub-id>
 </element-citation>
</ref>
